199 related articles for article (PubMed ID: 22267604)
21. Inv(16) acute myeloid leukemia cells show an increased sensitivity to cytosine arabinoside in vitro.
Tosi P; Visani G; Ottaviani E; Testoni N; Pellacani A; Tura S
Eur J Haematol; 1998 Mar; 60(3):161-5. PubMed ID: 9548414
[TBL] [Abstract][Full Text] [Related]
22. Enhanced cytarabine-induced killing in OGG1-deficient acute myeloid leukemia cells.
Owen N; Minko IG; Moellmer SA; Cammann SK; Lloyd RS; McCullough AK
Proc Natl Acad Sci U S A; 2021 Mar; 118(11):. PubMed ID: 33836581
[TBL] [Abstract][Full Text] [Related]
23. Genetic variants in cytosolic 5'-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia.
Mitra AK; Crews KR; Pounds S; Cao X; Feldberg T; Ghodke Y; Gandhi V; Plunkett W; Dolan ME; Hartford C; Raimondi S; Campana D; Downing J; Rubnitz JE; Ribeiro RC; Lamba JK
J Pharmacol Exp Ther; 2011 Oct; 339(1):9-23. PubMed ID: 21712425
[TBL] [Abstract][Full Text] [Related]
24. Effect of dexamethasone on the antileukemic effect of cytarabine: role of deoxycytidine kinase.
Jaramillo AC; Bergman AM; Comijn EM; Jansen G; Kaspers GJL; Cloos J; Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2020; 39(10-12):1346. PubMed ID: 32727269
[TBL] [Abstract][Full Text] [Related]
25. SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia.
Schneider C; Oellerich T; Baldauf HM; Schwarz SM; Thomas D; Flick R; Bohnenberger H; Kaderali L; Stegmann L; Cremer A; Martin M; Lohmeyer J; Michaelis M; Hornung V; Schliemann C; Berdel WE; Hartmann W; Wardelmann E; Comoglio F; Hansmann ML; Yakunin AF; Geisslinger G; Ströbel P; Ferreirós N; Serve H; Keppler OT; Cinatl J
Nat Med; 2017 Feb; 23(2):250-255. PubMed ID: 27991919
[TBL] [Abstract][Full Text] [Related]
26. Antibody-Targeted Cyclodextrin-Based Nanoparticles for siRNA Delivery in the Treatment of Acute Myeloid Leukemia: Physicochemical Characteristics, in Vitro Mechanistic Studies, and ex Vivo Patient Derived Therapeutic Efficacy.
Guo J; Russell EG; Darcy R; Cotter TG; McKenna SL; Cahill MR; O'Driscoll CM
Mol Pharm; 2017 Mar; 14(3):940-952. PubMed ID: 28146632
[TBL] [Abstract][Full Text] [Related]
27. Role of Chk1 and Chk2 in Ara-C-induced differentiation of human leukemia K562 cells.
Takagaki K; Katsuma S; Kaminishi Y; Horio T; Tanaka T; Ohgi T; Yano J
Genes Cells; 2005 Feb; 10(2):97-106. PubMed ID: 15676021
[TBL] [Abstract][Full Text] [Related]
28. miR-181a sensitizes resistant leukaemia HL-60/Ara-C cells to Ara-C by inducing apoptosis.
Bai H; Cao Z; Deng C; Zhou L; Wang C
J Cancer Res Clin Oncol; 2012 Apr; 138(4):595-602. PubMed ID: 22209977
[TBL] [Abstract][Full Text] [Related]
29. Biochemical modulation of aracytidine (Ara-C) effects by GTI-2040, a ribonucleotide reductase inhibitor, in K562 human leukemia cells.
Chen P; Aimiuwu J; Xie Z; Wei X; Liu S; Klisovic R; Marcucci G; Chan KK
AAPS J; 2011 Mar; 13(1):131-40. PubMed ID: 21191677
[TBL] [Abstract][Full Text] [Related]
30. Potentiation of in vitro ara-C cytotoxicity by ribonucleotide reductase inhibitors, cyclin-dependent kinase modulators and the DNA repair inhibitor aphidicolin in paediatric acute myeloid leukaemia.
Hubeek I; Peters GJ; Broekhuizen AJ; Sargent J; Gibson BE; Creutzig U; Kaspers GJ
Br J Haematol; 2005 Oct; 131(2):219-22. PubMed ID: 16197453
[TBL] [Abstract][Full Text] [Related]
31. MALAT1 knockdown inhibits proliferation and enhances cytarabine chemosensitivity by upregulating miR-96 in acute myeloid leukemia cells.
Hu N; Chen L; Wang C; Zhao H
Biomed Pharmacother; 2019 Apr; 112():108720. PubMed ID: 30970520
[TBL] [Abstract][Full Text] [Related]
32. 1-beta-D-arabinofuranosylcytosine activates tyrosine phosphorylation of p34cdc2 and its association with the Src-like p56/p53lyn kinase in human myeloid leukemia cells.
Yuan ZM; Kharbanda S; Kufe D
Biochemistry; 1995 Jan; 34(3):1058-63. PubMed ID: 7530044
[TBL] [Abstract][Full Text] [Related]
33. Increased activity of both CDK1 and CDK2 is necessary for the combinatorial activity of WEE1 inhibition and cytarabine.
Garcia TB; Fosmire SP; Porter CC
Leuk Res; 2018 Jan; 64():30-33. PubMed ID: 29175378
[TBL] [Abstract][Full Text] [Related]
34. Circumvention of ara-C resistance by aphidicolin in blast cells from patients with AML.
Sargent JM; Elgie AW; Williamson CJ; Lewandowicz GM; Taylor CG
Br J Cancer; 2001 Mar; 84(5):680-5. PubMed ID: 11237390
[TBL] [Abstract][Full Text] [Related]
35. Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies.
Herold N; Rudd SG; Ljungblad L; Sanjiv K; Myrberg IH; Paulin CB; Heshmati Y; Hagenkort A; Kutzner J; Page BD; Calderón-Montaño JM; Loseva O; Jemth AS; Bulli L; Axelsson H; Tesi B; Valerie NC; Höglund A; Bladh J; Wiita E; Sundin M; Uhlin M; Rassidakis G; Heyman M; Tamm KP; Warpman-Berglund U; Walfridsson J; Lehmann S; Grandér D; Lundbäck T; Kogner P; Henter JI; Helleday T; Schaller T
Nat Med; 2017 Feb; 23(2):256-263. PubMed ID: 28067901
[TBL] [Abstract][Full Text] [Related]
36. DUSP1 Signaling Pathway Regulates Cytarabine Sensitivity in Acute Myeloid Leukemia.
Sun H; Ren Y; Zhou X; Chen Q; Liu Y; Zhu C; Ruan Y; Ruan H; Tong H; Ying S; Lin P
Technol Cancer Res Treat; 2023; 22():15330338231207765. PubMed ID: 37872685
[No Abstract] [Full Text] [Related]
37. Differential effect of GM-CSF pretreatment on intracellular Ara-C metabolism in normal bone marrow mononuclear cells vs acute myeloid leukemia (AML) blasts.
Reuter C; Schleyer E; Rolf C; Wörmann B; Büchner T; Hiddemann W
Leukemia; 1997 Apr; 11(4):561-71. PubMed ID: 9096697
[TBL] [Abstract][Full Text] [Related]
38. Blasts from elderly acute myeloid leukemia patients are characterized by low levels of culture- and drug-induced apoptosis.
Garrido SM; Cooper JJ; Appelbaum FR; Willman CL; Kopecky K; Banker DE
Leuk Res; 2001 Jan; 25(1):23-32. PubMed ID: 11137557
[TBL] [Abstract][Full Text] [Related]
39. Tumour suppressive effects of WEE1 gene silencing in breast cancer cells.
Ghiasi N; Habibagahi M; Rosli R; Ghaderi A; Yusoff K; Hosseini A; Abdullah S; Jaberipour M
Asian Pac J Cancer Prev; 2014 Jan; 14(11):6605-11. PubMed ID: 24377575
[TBL] [Abstract][Full Text] [Related]
40. Exploring the Antitumor Mechanism of High-Dose Cytarabine through the Metabolic Perturbations of Ribonucleotide and Deoxyribonucleotide in Human Promyelocytic Leukemia HL-60 Cells.
Li Z; Guo JR; Chen QQ; Wang CY; Zhang WJ; Yao MC; Zhang W
Molecules; 2017 Mar; 22(3):. PubMed ID: 28335578
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]